Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
US12024560B2 · kind B2 · utility
0Cited by
4References
5Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 28, 2018 |
| Grant date | Jul 2, 2024 |
| Priority date | — |
| Expiry date | May 14, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB (CD32B). Also provided herein are methods for selectively activating immune responses in a subject using a therapeutic agent capable of targeting both an immune cell surface receptor and FcγRIIB.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.